Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2018

View Archived Issues

Revolution Medicines advances potent, orally available SHP-2 allosteric inhibitor

Phase I results presented for rebamipide prodrug SA-001

Sujanu combination tablets approved in Japan

New biomarkers and targets for cutaneous T-cell lymphomas found via N-glycoproteomic analysis

Novartis divesting stake in healthcare joint venture to GSK

Polyphor initiates phase III trial of murepavadin for nosocomial pneumonia

FDA grants priority review to sBLA for Opdivo plus Yervoy for MSI-H or dMMR colorectal cancer

Novel small molecules inhibit Escherichia coli FmlH to treat urinary tract infections

Servier initiates phase I study of MRG-110

Tyme initiates phase II trial of SM-88 in metastatic pancreatic cancer

Japanese Sakigake designation granted to AveXis' AVXS-101 for SMA type 1

Japan's MHLW grants Sakigake designation to JR-141 for Hunter's syndrome

European Commission expands indication for Feraccru

FDA grants breakthrough therapy designation to Pedmark

Krystal files IND with FDA for phase I/II study of KB-103 for dystrophic EB

Sirenas describes novel cyclic peptide analogues

Novel metabotropic glutamate mGlu7 receptor agonists synthesized at Takeda

Sichuan Kelun-Biotech Biopharmaceutical patents thrombopoietin receptor agonists

Shanghai Institute Materia Medica, Shanghai Haihe Pharmaceutical divulge new EZH2 inhibitors

Aurigene Discovery Technologies presents novel VISTA protein inhibitors

Japanese Sakigake designation granted to cancer programs

KIFC1 a potentially new and druggable target for colorectal carcinoma

Altimmune updates NasoVAX and HepTcell programs

Bardoxolone methyl granted Sakigake designation in Japan

AnaptysBio reports encouraging topline proof-of-concept data for ANB-020 in peanut allergy

Carna Biosciences enters joint research agreement with Sumitomo Dainippon Pharma

FDA advisory committee recommends approval of Lucemyra

Semglee biosimilar insulin glargine approved in E.U. and Australia

EMA validates application for Cabometyx for previously treated advanced HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...